Oncology
1 drug is in development for Platinum-resistant Ovarian Cancer.
- Companies
- 1
- Clinical trials
- 21
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Platinum-resistant Ovarian Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| CTIM-76 | Context Therapeutics Inc. (CNTX) |
About this indication
Platinum-resistant Ovarian Cancer context
Oncology·MeSH: Ovarian Neoplasms (D010051)
Narrower concept of MeSH descriptor Ovarian Neoplasms
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Platinum-resistant Ovarian Cancer?
BioSniper tracks 1 drug in development for Platinum-resistant Ovarian Cancer across 1 company.
How many clinical trials target Platinum-resistant Ovarian Cancer?
There are 21 clinical trials targeting Platinum-resistant Ovarian Cancer tracked by BioSniper.
What is the prevalence of Platinum-resistant Ovarian Cancer?
The estimated prevalence of Platinum-resistant Ovarian Cancer is approximately 24.0 per 100,000 population.